Citi raised the firm’s price target on Veradermics (MANE) to $135 from $120 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MANE:
- Veradermics Faces Financing Risk as Cashless Pre-Funded Warrants Offer Little to No Capital Infusion
- Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year
- Veradermics Boosts Capital Through Public Offering and Warrants
- Veradermics 3.84M share Secondary priced at $100.00
- Veradermics announces offering of 3.35M shares of common stock